- Email: [email protected]
4485093 Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
New Patents
sensitized with antibody to antigen of lymphocyte and sheep red cells or another kind of antibody-sensitized microcapsules that are optically distinguishable from the first antibodysensitized microcapsules, to lymphocyte at the same time and thereafter independently measuring respective cells that are optically distinguishable from each other. The operation for the measurement is extremely simple and neither skill nor special equipment is required.
I I~*-
i
u !i
'i !i } !
~t
=
!i
} i""
r'i,,
4483929 LIPOSOMES WITH GLYCOLIPIDLINKED ANTIBODIES Frank C Szoka assigned to Liposome Technology Incorporated Lipid vesicles, labelled with encapsulated reporter compositions and bound to antibodies comprise a new class of immunoreagent, useful in immunoassays for ligands.
An improved process for the isolation and purification of HIFNs is disclosed wherein a partially purified preparation of the HIFN is sequentially passed through an antibody affinity column and a reversed-phase high performance liquid chromatographic column. Organic solvents used during the elution are extracted and the protein concentrated for subsequent use.
4485093 4484923 METHOD FOR ADMINISTERING IMMUNOPOTENTIATOR Alfred Amkraut, Agusto Martins assigned to ALZA Corporation
IMMUNOTOXIN CONJUGATE WHICH COMPRISES ARSANILIC ACID, USEFUL FOR TREATING MALIGNANT TUMORS, PARTICULARLY PANCREATIC CANCER Richard G Runge
The invention pertains to the administration of an immunopotentiator to activate an immune t:esponse. The administration comprises the controlled and continuous administration of the immunopotentiator leading to a high immune response with adequate persistancy, while simultaneously and substantially reducing or eliminating inflammatory reactions usually accompanying depot-type administration.
An immunotoxin conjugate, useful for treating malignant tumors in mammals, which consists of arsanilic acid and tumor specific antibodies covalently bound to a polyglutamic acid linking agent is taught. The conjugate selectively delivers arsanilic acid to a tumor, killing the tumor cells and exhibiting little or no toxicity to normal cells. The conjugate is effective in treating human pancreatic cancer.
4485175
4485017 ISOLATION OF HUMAN INTERFERON BY IMMUNOSORBENT AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
METHOD FOR THREE-VOLUME DIFFERENTIAL DETERMINATION OF LYMPHOCYTE, MONOCYTE AND GRANULOCYTE POPULATIONS OF LEUKOCYTES
Yin H Tan, Heidi Smith-Johannsen, Calgary, Canada assigned to Cetus Corporation
Stephen Ledis, Ted Sena, Harold Crews, James H Carter assigned to Coulter Electronics Inc
sensitized with antibody to antigen of lymphocyte and sheep red cells or another kind of antibody-sensitized microcapsules that are optically distinguishable from the first antibodysensitized microcapsules, to lymphocyte at the same time and thereafter independently measuring respective cells that are optically distinguishable from each other. The operation for the measurement is extremely simple and neither skill nor special equipment is required.
I I~*-
i
u !i
'i !i } !
~t
=
!i
} i""
r'i,,
4483929 LIPOSOMES WITH GLYCOLIPIDLINKED ANTIBODIES Frank C Szoka assigned to Liposome Technology Incorporated Lipid vesicles, labelled with encapsulated reporter compositions and bound to antibodies comprise a new class of immunoreagent, useful in immunoassays for ligands.
An improved process for the isolation and purification of HIFNs is disclosed wherein a partially purified preparation of the HIFN is sequentially passed through an antibody affinity column and a reversed-phase high performance liquid chromatographic column. Organic solvents used during the elution are extracted and the protein concentrated for subsequent use.
4485093 4484923 METHOD FOR ADMINISTERING IMMUNOPOTENTIATOR Alfred Amkraut, Agusto Martins assigned to ALZA Corporation
IMMUNOTOXIN CONJUGATE WHICH COMPRISES ARSANILIC ACID, USEFUL FOR TREATING MALIGNANT TUMORS, PARTICULARLY PANCREATIC CANCER Richard G Runge
The invention pertains to the administration of an immunopotentiator to activate an immune t:esponse. The administration comprises the controlled and continuous administration of the immunopotentiator leading to a high immune response with adequate persistancy, while simultaneously and substantially reducing or eliminating inflammatory reactions usually accompanying depot-type administration.
An immunotoxin conjugate, useful for treating malignant tumors in mammals, which consists of arsanilic acid and tumor specific antibodies covalently bound to a polyglutamic acid linking agent is taught. The conjugate selectively delivers arsanilic acid to a tumor, killing the tumor cells and exhibiting little or no toxicity to normal cells. The conjugate is effective in treating human pancreatic cancer.
4485175
4485017 ISOLATION OF HUMAN INTERFERON BY IMMUNOSORBENT AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
METHOD FOR THREE-VOLUME DIFFERENTIAL DETERMINATION OF LYMPHOCYTE, MONOCYTE AND GRANULOCYTE POPULATIONS OF LEUKOCYTES
Yin H Tan, Heidi Smith-Johannsen, Calgary, Canada assigned to Cetus Corporation
Stephen Ledis, Ted Sena, Harold Crews, James H Carter assigned to Coulter Electronics Inc